Puma Biotechnology (PBYI) Stock Analysis & Winston Score

Puma Biotechnology is a small pharmaceutical company that develops and sells cancer drugs. Its main product is Nerlynx (neratinib), a pill used to treat a type of breast cancer called HER2-positive breast cancer. The drug is sold to patients who have already been treated with another cancer medicine, and it is prescribed by oncologists at hospitals and cancer clinics. Puma makes money by selling Nerlynx directly in the United States and through licensing deals with partners who sell it in other countries, including parts of Europe and Asia. The company is small, with a market cap around $500 million, but its 74% gross margin shows the drug carries strong pricing power once development costs are covered. The biggest risk Puma faces is its heavy dependence on a single product — if Nerlynx loses market share to competing therapies or faces generic competition, revenue could fall sharply.